MarketResearchReports.biz has recently announced the addition of a new market research report to its huge database of research studies. The research study, titled “Opportunity Analyzer: Opioid-induced Constipation - Opportunity Analysis and Forecasts To 2019,” provides a comprehensive analysis of the global market for opioid-induced constipation (OIC), emphasizing on the disease overview, potential patient population, present treatment options, research and development strategies, and pipeline assessment and valuation analysis. The valued inputs given by the industry experts in the research study assist the major players in the market in designing their strategies and policies.
The research report further elaborates on factors such as the presence of several unmet requirements in the present treatments for OIC. Its talks about the drugs that are currently under development and examines if they can fulfil the unmet requirements in the global OIC market in the forecast period. According to the research study, the late-stage pipeline of OIC is substantially jammed with numerous drugs of a similar class: PAMORAs. The study discusses the significant impact of the drugs on the overall OIC market and which drugs will register the highest sales numbers and growth rate in the next few years. Furthermore, the research report talks about the forecast statistics provided in the research report, which cover the drugs included in every therapeutic class, percentage of drug-treated patients, general pricing assumptions, pricing of pipeline agents, and individual drug assumptions.
Opioid-induced constipation is an innovative and a fast-growing market, which is presently dominated by the OTC laxatives segment. The study further studies how the introduction of highly targeted oral prescriptions drugs will transform the overall scenario of OIC treatment across the globe in the forecast period. The OTC laxatives segment is estimated to witness significant growth throughout the forecast period. Moreover, the global OIC market is projected to grow rapidly in the coming years owing to the launch of numerous highly targeted, anticipated, and efficacious treatments options, coupled with a competitive and congested late-stage clinical drug pipeline.
The growing patient pool suffering from OIC is one of the major drivers that is fueling the growth of the overall market. Moreover, the relaxation of rules and regulations about opioid treatment, especially for patients having chronic non-cancer pain, is a major driver of the market. Thus, the use of opioids has risen substantially in the last fifteen years and is further expected to increase in the near future. Some of the promising drugs for pipeline assessment mentioned in the research report are Bevenopran, Oral Relistor, Dolcanatide, Axelopran, Nalcol, Naldemedine, and other innovative early-stage approaches.
In recent years, several products have been approved with heavy restrictions prohibitive to their use by the majority of OIC patients. Nevertheless, the global OIC therapeutic market is estimated to register an enormous growth rate in the forecast period. This growth can be attributed to the shift in the algorithm of OIC treatment due to the introduction of several drugs. Thus, the competitive landscape of the OIC market will grow in the near future.
To order report Call Toll Free: 866-997-4948 or send an email on email@example.com